Inclusion Criteria:  Meet the diagnostic criteria for immune thrombocytopenia; Untreated hospitalized patients or patients from the clinic, may be male or female, between the ages of 18~ 80 years; To show a platelet count <30 * 10^9/L, or with bleeding manifestations, or both; Willing and able to sign written informed consent ITP patients with hepatitis virus infection or ITP patients with abnormal liver function at the time of enrollment, i.e., ITP patients with indications for diammonium glycyrrhizinate enteric-coated capsule, should be separately stratified.  Exclusion Criteria:  secondary thrombocytopenia; severe immune-deficiency; active or previous malignancy; HIV virus infection, tuberculosis, or other active infection (sepsis, pneumonia, or abscess); pregnancy or lactation; diabetes; hypertension; cardiovascular diseases; severe kidney function impairment; psychosis; osteoporosis; inflammatory bowel disease or gastric disease; arterial or venous thromboembolism within the 6 months before screening or patients who required anticoagulant treatment; an organ or haematopoietic stem-cell transplantation; neutrophil count of less than 1500 cells per mm³; glycosylated haemoglobin less than 8%; partial thromboplastin time 1∙5 times or less the upper limit of normal (ULN); •clinical electrocardiogram changes; history of primary immunodeficiency; neoplastic disease within the past 5 years; corrected QT interval greater than 450 ms for men and greater than 470 ms for women; substance misuse within the previous 12 months; people who could not adhere to the protocol or were planning to have a surgical procedure in 6 months.